Abstract
Sodium (Na) channels are essential for cardiac electrical activity. Cardiac Na channel dysfunction, inherited or acquired, can induce life-threatening conduction and arrhythmia disorders. Inherited Na channel dysfunction may put affected patients at a greater risk for these complications when channel-modifying drugs are prescribed. This study addressed pharmacogenetic effects in three well-described Na channel-related diseases: long QT syndrome type 3, Brugada syndrome and inherited cardiac conduction disease. A review of the currently available literature on cardiac Na channel-modulating drugs was undertaken. An overview is given of the known risks of development of the previously mentioned complications of commonly prescribed drugs in patients affected with Na channel-related diseases and the underlying mechanisms.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Action Potentials / drug effects
-
Arrhythmias, Cardiac / chemically induced
-
Arrhythmias, Cardiac / genetics
-
Arrhythmias, Cardiac / metabolism*
-
Arrhythmias, Cardiac / physiopathology
-
Brugada Syndrome / chemically induced
-
Brugada Syndrome / genetics
-
Brugada Syndrome / metabolism*
-
Brugada Syndrome / physiopathology
-
Cardiovascular Agents / adverse effects*
-
Electrocardiography
-
Genetic Predisposition to Disease
-
Humans
-
Long QT Syndrome / chemically induced
-
Long QT Syndrome / genetics
-
Long QT Syndrome / metabolism*
-
Long QT Syndrome / physiopathology
-
Mutation*
-
Myocardium / metabolism*
-
Pedigree
-
Pharmacogenetics*
-
Protein Conformation
-
Risk Factors
-
Sodium Channels / chemistry
-
Sodium Channels / drug effects
-
Sodium Channels / genetics
-
Sodium Channels / metabolism*
Substances
-
Cardiovascular Agents
-
Sodium Channels